فهرست مطالب pedram talezadeh shirazi

Thyroid cancer (TC) is the most common endocrine malignancy. Thyroidectomy and radiotherapy are common treatment modalities for patients with undifferentiated TC (UTC), and sorafenib is usually recommended to prevent a recurrence. However, malignant cells may evade chemotherapy-induced apoptosis, and combination therapy was developed to achieve better outcomes. This study investigated whether eugenol in combination with sorafenib was more effective than either substance individually in triggering apoptosis in the UTC. The IC50 of sorafenib and eugenol was determined in a UTC cell line (8305C) by MTT assay, and their synergistic effect in combination therapy was investigated. Flow cytometry was used to evaluate the rate of apoptosis in treated cells. To confirm that cell death occurred through apoptosis, immunoblotting was used to determine the relative cleavage of caspase-8 and caspase-9. The IC50 of sorafenib was 20 µM, and that of eugenol was 2100 µM. The sorafenib-eugenol combination (1:105) showed synergistic effects at concentrations equal to or less than their IC50. The rate of apoptosis induction was higher in cells treated with eugenol or the eugenol-sorafenib combination compared to sorafenib-treated cells. The relative intensity of cleaved/un cleaved forms of caspase-8 increased in eugenol-treated cells compared to sorafenib-treated cells.Sorafenib and eugenol at concentrations equal to or less than their IC50 had a synergistic effect in 8305C cells. The most potent apoptotic effect was achieved with sorafenib and eugenol at their IC50. Lower doses of sorafenib could be used with eugenol to improve its efficacy while reducing its side effects.

Hepatitis B virus infection is a worldwide health problem. Vertical transmission is a route of Hepatitis B virus infection that is regarded as a considerable factor in Hepatitis B virus prevention program all over the world. This study was conducted to screen the hepatitis B surface antigen, hepatitis B surface antibody and hepatitis B e antigen in pregnant women. From September to October 2009, two hundred fifty pregnant women in Zeynabieh hospital in Shiraz, Iran, were recruited consecutively to this study at the time of their delivery. Their sera were examined for detection of hepatitis B surface antigen, hepatitis B e antigen and hepatitis B surface antibody, using enzyme-linked immunosorbent assay. Different demographic data (i.e. age, nationality, vaccination and family history of Hepatitis B virus infection) were investigated to determine the presence or absence of hepatitis B surface antigen, hepatitis B e antigen and hepatitis B surface antibody. Among 250 subjects, the prevalence of hepatitis B surface antigen and hepatitis B surface antibody was 1.2 % and 50%, respectively. Demographic data that showed significant association with prevalence of hepatitis B surface antigen were family history of Hepatitis B virus infection (X2 = 7.735, P = 0.05), age (X2 = 3.762, P = 0.05) and nationality (X2 = 5.41, P = 0.02). The findings of this study recommended the necessity of hepatitis B surface antigen screening test for pregnant women especially for those younger than 25 years of age and with the family history of Hepatitis B virus infection and also for Afghani residents.